Treatments that have the potential to both cure rectal cancer and preserve the rectum may offer a considerable advantage over total mesorectal excision (TME), which provides excellent tumor control but often entails a permanent colostomy or a coloanal anastomosis. In this issue of JAMA Surgery, Stijns et al1 report the results of a multicenter, nonrandomized feasibility study that investigated whether chemoradiotherapy followed by local excision (CRT-LE) is an oncologically acceptable rectum-preserving strategy for rectal cancer in stage cT1 3N0. Although the study was not powered to demonstrate the efficacy of CRT-LE compared with TME (which is the benchmark for any new treatment), it adds to the growing body of evidence supporting CRT-LE as an alternative to TME.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Garcia-Aguilar J. Chemoradiotherapy and Local Excision for Organ Preservation in Early Rectal Cancer—The End of the Beginning? JAMA Surg. 2019;154(1):54–55. doi:https://doi.org/10.1001/jamasurg.2018.3760
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: